Welcome to our dedicated page for Eagle Pharmaceut news (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on Eagle Pharmaceut stock.
Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) generates a steady flow of corporate, product and governance updates that are relevant to investors following EGRX news. As a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise, Eagle regularly issues press releases about its commercial portfolio, pipeline programs and capital structure decisions.
Company announcements describe a portfolio that includes PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO, as well as BYFAVO and BARHEMSYS historically commercialized through its wholly owned subsidiary Acacia Pharma Inc. News items have covered transactions such as a royalty purchase agreement to monetize BENDEKA royalties and the divestiture of the U.S. marketing authorization for Barhemsys (amisulpride) to LXO Group, with Eagle noting that proceeds would support ongoing operations and debt repayment.
Governance and capital markets developments are also a recurring theme in Eagle’s news flow. The company has reported on the adoption and amendment of a limited duration stockholder rights plan, changes to the plan’s purchase price and duration, and cooperation agreements with significant stockholders involving board appointments. In addition, Eagle issues updates on its annual meeting of stockholders, proxy material availability, and the release of audited and unaudited financial statements.
Investors monitoring EGRX news can use this page to follow Eagle’s disclosures on its oncology and critical care products, CNS/metabolic critical care pipeline, financing transactions, and corporate governance actions. Regularly reviewing these updates can help readers understand how Eagle describes the evolution of its product portfolio, pipeline priorities and capital structure over time.
Eagle Pharmaceuticals, Inc. (EGRX) announced the availability of its pre-recorded presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference. The presentation can be viewed via a link provided in the release and will also be available on Eagle's website for 30 days. Additionally, CEO Scott Tarriff and CFO Brian Cahill will engage in 1x1 meetings on December 1, 2020, which can be requested through Piper Sandler. The company remains focused on developing innovative medicines for critical care and oncology.
Eagle Pharmaceuticals (Nasdaq: EGRX) reported a strong financial performance for Q3 2020, with total revenue reaching $49.9 million, up from $41.1 million in Q3 2019. Net income for the quarter was $7.1 million, or $0.52 per share, compared to a net loss of $2.4 million last year. The company received FDA Priority Review for its vasopressin ANDA, added key executives to its leadership, and approved a $25 million share repurchase plan. Despite COVID-19 delays, Eagle remains optimistic about upcoming product launches and continued growth.
Eagle Pharmaceuticals (Nasdaq: EGRX) has appointed four new executives to strengthen its clinical and commercialization teams: Dr. Judi Ng-Cashin as EVP and Chief Medical Officer, John Kimmet as EVP of Oncology and Acute Care Marketing, Dr. Valentin R. Curt as SVP of Clinical Drug Development, and Dr. Gaozhong Zhu as SVP of Pharmaceutical Development. Brian Cahill has been promoted to Chief Financial Officer. The new leadership is expected to bolster Eagle's efforts in advancing its pipeline products, including EA-114, and support future growth strategies.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced it will release its 2020 third-quarter financial results on November 2, 2020, prior to market opening. CEO Scott Tarriff and CFO Pete Meyers will host a conference call at 8:30 a.m. ET to discuss the results. Investors can access the call by dialing 866-342-8591 (U.S.) or 203-518-9713 (International). A replay will be available for one week after the call. Eagle is a fully integrated pharmaceutical company focused on developing innovative medicines to improve patients' lives.